| 抗骨质疏松治疗药物研究的新进展 |
| 投稿时间：2017-08-24 修订日期：2017-10-16 点此下载全文 |
| 引用本文：贾文斌,刘超,邹燕.抗骨质疏松治疗药物研究的新进展[J].药学实践杂志,2017,35(6):490~494,542 |
| 摘要点击次数: 968 |
| 全文下载次数: 1641 |
|
|
| 中文摘要:骨质疏松是一种常见的全身性骨代谢疾病，主要表现为骨密度与骨量的下降，从而导致继发性骨折。目前，随着其发病率不断增高，骨质疏松已经成为一个世界范围的健康问题和当前医学的研究热点。骨吸收抑制剂主要作用于破骨细胞，通过抑制破骨细胞分化成熟，减少骨吸收；骨形成促进剂主要作用于成骨细胞，激活其骨形成功能，并且有重建骨组织的效应；骨矿化物是防治骨质疏松的基础药物，包括钙剂和维生素D；解偶联剂种类较为单一，代表药物为雷尼酸锶。主要对以上四大类抗骨质疏松药物的研究进展进行介绍。 |
| 中文关键词:骨质疏松 药物 治疗 骨吸收抑制剂 骨形成促进剂 骨矿化促进剂 |
| |
| Research progress on drugs in osteoporosis therapy |
|
|
| Abstract:Osteoporosis (OP) is a systemic bone metabolism disease characterized by a systemic impairment of bone mass, strength, and microarchitecture, which will be result in increasing the propensity of fragility fractures. In recent years, OP becomes a worldwide health problem and a hotspot in medical research due to its increasing incidence. Anti-resorptive drugs inhibit osteoclast differentiation and maturation in order to reduce bone resorption; Bone-anabolic drugs promote the bone formation function of osteoblast and reconstruct bone tissue; Bone mineralization-acceleration drugs are the basic material for prevention and treatment of osteoporosis, including calcium and vitamin D; Strontium ranelate is the representative drug of uncoupling agents. In this paper, the current progress of osteoporosis treatments were reviewed including these proposed drugs. |
| keywords:osteoporosis drugs therapy anti-resorptive drugs bone-anabolic drugs bone mineralization-acceleration drugs |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
